TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3440508
Drug: Alginate/antacid chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate/antacid chewing tablets and metoclopramide
Study: 2486782
Drug: Overall tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall tolerance of triphasic preparation (LOGYNON)
Study: 31952632
Drug: Xylazine (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (0.20 mg kg‐1)
Study: 31952632
Drug: Dexmedetomidine (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.005 mg kg‐1)
Study: 25091954
Drug: Brilliant blue
Normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brilliant blue G (BBG) under air infusion (group 1)
Study: 25091954
Drug: Brilliant blue
Normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brilliant blue G (BBG) injected into the vitreous cavity (group 2)
Study: 23021155
Drug: Mustard (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mustard (21 g)
Study: 23021155
Drug: Horseradish (8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horseradish (8.3 g)
Study: 23021155
Drug: Ginger (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (20 g)
Study: 23021155
Drug: Black pepper
Normalized name: Black Pepper
DrugBank: Black pepper (DB10557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black pepper (1.3 g)
Study: 22036523
Drug: Lyprinol(®) 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyprinol(®) 200mg daily for 8 weeks
Study: 19463379
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa antagonist
Study: 19463379
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (no GP IIb/IIIa antagonist)
Study: 11332869
Drug: propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (40 mg twice daily)
Study: 9522971
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin administration by caregivers
Study: 3508553
Drug: Etretinate 25
Normalized name: etretinate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate 25 mg
Study: 3508553
Drug: Etretinate 50
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate 50 mg
Study: 3508553
Drug: Etretinate 75
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate 75 mg
Study: 3508553
Drug: Etretinate 100
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate 100 mg
Study: 27067604
Drug: Module group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Module group (MG)
Study: 2647494
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin plus dipyridamole
Study: 12542565
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with transdermal 17‐beta oestradiol and medroxyprogesterone acetate
Study: 12542565
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for CHD
Study: 11505388
Drug: 2 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of the same chemotherapy after 6 cycles of induction chemotherapy
Study: 11505388
Drug: (sub)total lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: (sub)total lymph node irradiation after 6 cycles of induction chemotherapy
Study: 9248317
Drug: Formoterol (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (long-acting beta 2-agonist)
Study: 8256188
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and mezlocillin (gentamicin 1.0 to 1.5 mg/kg every 8 hours; mezlocillin 3 to 4 grams every 4 to 6 hours)
Study: 31370128
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral prednisolone twice daily for four days
Study: 28882536
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2 on day 1 every 3 weeks
Study: 28882536
Drug: Gemcitabine 675
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 675 mg/m2 on days 1 and 8 and docetaxel 75 mg/m2 on day 8 every 3 weeks
Study: 17673814
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2, every 3 weeks)
Study: 17673814
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2, every 3 weeks) + 5'DFUR (600 mg/body)
Study: 15152060
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy plus a single-chamber ICD
Study: 11332171
Drug: Beractant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beractant (100 mg kg-1) administered 2 hours after the first dose
Study: 11332171
Drug: Beractant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beractant (100 mg kg-1) administered 6 hours after the first dose
Study: 7846948
Drug: Oral digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral digoxin (0.125 mg three times daily up to 0.25 mg twice daily)
Study: 7846948
Drug: Oral digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral digoxin (0.125 mg twice daily) and quinidine hydrogen sulphate (750‐1000 mg daily)
Study: 7846948
Drug: Oral digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral digoxin (0.125 mg three times daily) and flecainide (200‐300 mg daily)
Study: 9224961
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (400 mg every 8 hours for 30 days) + Rifabutin (300 mg once daily on days 16-30)
Study: 9164416
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (400 mg every 8 hours for 30 days)
Study: 7737957
Drug: Fluoxetine (antidepressant)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (antidepressant) for 12 weeks
Study: 2183734
Drug: Forced diuresis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced diuresis, chemotherapy, and plasmapheresis (group 2)
Study: 2183734
Drug: Forced diuresis
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced diuresis and chemotherapy (group 1)
Study: 457316
Drug: Topical salicylic
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylic acid in hydrophilic ointment applied to skin with removed stratum corneum
Study: 457316
Drug: Topical salicylic
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylic acid in hydrophilic ointment applied to intact skin
Study: 457316
Drug: Topical salicylic
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylic acid in polyethylene glycol 400 vehicle
Study: 28591240
Drug: Sealant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealant treatment (n = 28)
Study: 28591240
Drug: Restorative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorative treatment (n = 26)
Study: 24843061
Drug: Follow-up formula
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up formula (FUF) with 25 mg DHA, 1.2 g PDX/GOS, and 8.7 mg yeast β‐glucan per serving, 3 servings per day for 28 weeks
Study: 22773430
Drug: Acebron™ 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebron™ 4 mg (Test)
Study: 22773430
Drug: Neo‐Sintrom™ 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo‐Sintrom™ 4 mg (Reference)
Study: 8683518
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of %WL, BMI, and MAMC
Study: 1522190
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone 12.5 mg q.d. starting from the day after the HCG trigger, increased to 25 mg q.d. on the day of embryo transfer
Study: 6347232
Drug: Aspirin (0.3-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (0.3-1.2 g single dose)
Study: 6347232
Drug: Other nonsteroidal
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other nonsteroidal anti-inflammatory drugs (oral challenge)
Study: 10399795
Drug: Glucocorticoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid therapy
Study: 25867415
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (CsA) alone
Study: 25867415
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-dose hormone and low-dose CsA
Study: 26864236
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic therapy
Study: 26864236
Drug: Conventional glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glycemic therapy
Study: 14966097
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg i.v. before chemotherapy plus 4 mg orally every 6 hours for four doses (arm A)
Study: 14966097
Drug: Dexamethasone 24
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 24 mg i.v. single dose before chemotherapy (arm B)
Study: 14966097
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg i.v. single dose before chemotherapy (arm C)
Study: 11337977
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 3.9 g daily for 63 days
Study: 29544472
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA) - 2 g 2 hours before incision, 1 g at 6 and 12 hours after surgery
Study: 29544472
Drug: Intra-articular tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tranexamic acid (TXA) - 3 g in 100 mL of saline solution
Study: 20113305
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus waiting list for DBT (TAU+WL)
Study: 12847484
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to kitchen Bla g 1 levels greater than 1 U/g
Study: 9001834
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg administered at bedtime
Study: 2870754
Drug: Active trial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active trial or standard medication
Study: 26856220
Drug: General hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: General hydration (control group) with <500 mL normal saline at a normal rate (0.5 or 1 mL/kg.h)
Study: 22873210
Drug: Interactive neurostimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive neurostimulation (INS) therapy
Study: 22197956
Drug: Low-frequency force
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency force steadiness practice in plantar flexor muscles (5 sets of 60-s contraction at 10% and 20% MVC, once or twice a week for 4 weeks)
Study: 16809568
Drug: ADMA (0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADMA (0.10 mg ADMA/kg per min)
Study: 12780424
Drug: Advice plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice plus iron supplement (60 mg Fe2+ - Ferromax)
Study: 12780424
Drug: Advice plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice plus iron supplement (3.6 mg heme iron plus 24 mg Fe2+ - Hemofer)
Study: 9360504
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (2.5 mg)
Study: 9360504
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (5 mg)
Study: 9360504
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (10 mg)
Study: 9360504
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (E2; 2 mg, orally) continuously combined with dydrogesterone (15 mg)
Study: 3900846
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (5 mg/dL)
Study: 24694337
Drug: 17β‐estradiol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐estradiol (0.1 mg/d via continuous delivery skin patch)
Study: 24694337
Drug: Progesterone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (100 mg/d via vaginal insert)
Study: 24694337
Drug: Testosterone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (12.5 mg/d via skin gel)
Study: 22319034
Drug: High-calorie diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie diet and sedentary lifestyle with prednisolone (37.5 mg once daily)
Study: 20926001
Drug: Topical ionized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ionized solution (IS)
Study: 20926001
Drug: Topical saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical saline solution (placebo)
Study: 18618034
Drug: 17% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% carbamide peroxide gel
Study: 9807138
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel
Study: 18618034
Drug: 0% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% carbamide peroxide gel (control group)
Study: 12037720
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (retinol) at a dose of 50,000 IU/d for 10 days
Study: 12037720
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg T(3) after 10 days of PL treatment
Study: 12037720
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg T(3) after 10 days of vitamin A treatment
Study: 10404854
Drug: Acebutolol 200
Normalized name: acebutolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 200 mg once daily
Study: 2184330
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization with killed Haemophilus influenzae
Study: 7023086
Drug: Intrathecal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal and peridural injection of 0.5 ml (= 10 mg) Triamcinolone hexacetonide
Study: 31450986
Drug: Crystalloid-based prime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid-based prime solution
Study: 31450986
Drug: Erythrocyte-based prime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocyte-based prime solution (control)
Study: 28079534
Drug: Olmesartan 20mg
Normalized name: HCTZ 12.5/OLMESARTAN 20MG TAB
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20mg once daily for 16 weeks
Study: 28079534
Drug: Azilsartan 20mg
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan 20mg once daily for 16 weeks
Study: 24197518
Drug: Red LED
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red LED therapy (630 ± 10 nm)
Study: 24197518
Drug: Infrared LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared LED therapy (850 ± 10 nm)
Study: 24197518
Drug: Infrared laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared laser therapy (780 nm) - Positive control group
Study: 12669392
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for malignant gliomas
Study: 12669392
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy for germinoma and primary CNS lymphoma
Study: 12669392
Drug: IMRT (Intensity-Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT (Intensity-Modulated Radiation Therapy)
Study: 9296277
Drug: Innogem 300
Normalized name: Innofem
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innogem 300 mg capsule
Study: 8345499
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (10 mg nitrendipine plus 120 mg verapamil)
Study: 8345499
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy (240 mg verapamil or 20 mg nitrendipine)
Study: 3027839
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of itraconazole per day for seven days
Study: 20299990
Drug: Closed-loop anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop anaesthesia delivery system (CLADS) with continuous infusion of propofol
Study: 20299990
Drug: Manual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual administration of propofol adjusted by clinician
Study: 18619256
Drug: Zhi‐Xin‐Fang combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhi‐Xin‐Fang combined with standard western medicines
Study: 18619256
Drug: Standard western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard western medical therapy
Study: 15150185
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g once a day
Study: 11440287
Drug: Ezetimibe 20
Normalized name: atorvastatin-ezetimibe 20 mg-10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 20 mg
Study: 11440287
Drug: Ezetimibe (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (both doses)
Study: 8016771
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (40 mg)
Study: 7828692
Drug: Inhaled lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lysine acetylsalicylate (modified protocol)
Study: 23054350
Drug: Ecologically‐Based Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecologically‐Based Family Therapy (EBFT)
Study: 12908663
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (2000 estimates)
Study: 2880755
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g every 8th hour for 24 hours followed by cefadroxil 0.5 g twice daily for 6 days
Study: 2880755
Drug: Cefuroxime and
Normalized name: cefuroxime and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime and cefadroxil (treatment)
Study: 24405007
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment intervention using a handheld, vibrating stimulation device
Study: 22968527
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g over 10 minutes followed by 1 g over eight hours)
Study: 15264116
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/day for 12 weeks
Study: 12271297
Drug: AE-941 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AE-941 at 240 mL/d
Study: 12271297
Drug: AE-941 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AE-941 at 120 mL/d
Study: 12271297
Drug: AE-941 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AE-941 at 60 mL/d
Study: 12271297
Drug: AE-941 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AE-941 at 30 mL/d
Study: 12271297
Drug: AE-941 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AE-941 (all doses)
Study: 12271297
Drug: Nonserious drug-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonserious drug-related adverse events
Study: 7911530
Drug: Celiprolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (0.15 mg/kg, intravenous)
Study: 7911530
Drug: Metoprolol (intravenous)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (intravenous)
Study: 30965344
Drug: Dexamethasone 25
Normalized name: dexamethasone 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 25 mg/m2 daily for 4 days, repeated every 28 days over 32 weeks (first trial)
Study: 30965344
Drug: Dexamethasone 50
Normalized name: Dexamethasone 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 50 mg/m2 every 4 weeks for 12 weeks, followed by 25 mg/m2 every 4 weeks for 36 weeks (second trial)
Study: 14518142
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei and Lactobacillus acidophilus (10(10)-10(12) CFU/g)
Study: 14518142
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (10(10)-10(12) CFU/g)
Study: 16881093
Drug: Arthroscopic synovectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic synovectomy (AS) followed by intraarticular corticosteroid (IAC) treatment
Study: 10677890
Drug: Nebulized anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized anaesthetics (10 ml of 1% trimecain)